KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 4

Effect of intravitreal bevacizumab on macular thickness: exploring serum and vitreous proangiogenic biomarkers in patients with diabetic macular edema

Syed Shoaib AHMED
Abrar Ahmed MALIK
Masoom KHAN
Roquyya GUL
Tayyaba Gul MALIK
Muhammad KHALIL
Sayfa
833–839
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The effect of IVBon different proangiogenic biomarkers indicated a complex interplay of other factors in DME.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: This study evaluates diabetic macular-edema (DME) patients for the effect of intravitreal bevacizumab (IVB)injection on macular thickness and proangiogenic biomarkers in serum and vitreous.Materials and methods: Forty DME patients were analyzed for macular thickness (MT).
📊
Temel Bulgular & Veri:Twelve proangiogenic biomarkers in serumand vitreous were analyzed before and after IVB.Results: Significant decrease in MT with vitreal vascular endothelial growth factor-A (VEGF-A) was observed as expected after IVB,while serum VEGF-A did not follow a decreasing trend in contrast to VEGF-C, which decreased both in serum and vitreous.
💡
Sonuç & Katkı:The effect of IVBon different proangiogenic biomarkers indicated a complex interplay of other factors in DME.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: This study evaluates diabetic macular-edema (DME) patients for the effect of intravitreal bevacizumab (IVB)injection on macular thickness and proangiogenic biomarkers in serum and vitreous.Materials and methods: Forty DME patients were analyzed for macular thickness (MT). Twelve proangiogenic biomarkers in serumand vitreous were analyzed before and after IVB.Results: Significant decrease in MT with vitreal vascular endothelial growth factor-A (VEGF-A) was observed as expected after IVB,while serum VEGF-A did not follow a decreasing trend in contrast to VEGF-C, which decreased both in serum and vitreous. Othervitreal factors like bone morphogenetic protein-9 (BMP9) and fibroblast growth factor (FGF) were also significantly decreased, whileendothelial growth factor (EGF) increased following IVB. Before IVB, significant negative correlations were vitreous BMP9 with serumFGF, vitreous human growth factor (HGF) and interleukin-8 (IL-8) with serum endothelin, and vitreous and serum FGF and serumplacental growth factor (PLGF) with EGF. After IVB, negative correlations in serum vs. vitreous were found for both HGF and PLGFwith BMP9, and angiopoietin with FGF. Cube average thickness was negatively correlated with serum FGF and positively correlatedwith vitreous PLGF and endothelin.Conclusion: Vascular endothelial growth factors are not the only factors that cause macular edema in diabetic patients. The effect of IVBon different proangiogenic biomarkers indicated a complex interplay of other factors in DME.

🔖

Bu Makaleye Atıf Yap

AHMED, S. S., MALIK, A. A., KHAN, M., GUL, R., MALIK, T. G., KHALIL, M. (2022). Effect of intravitreal bevacizumab on macular thickness: exploring serum and vitreous proangiogenic biomarkers in patients with diabetic macular edema. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 4, 833–839. https://ajindex.com/articles/610254

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Therapeutics 2001; 69: 89-95.
  2. World Health Organization, International Programme on Chemical Safety. Biomarkers in Risk Assessment: Validity and Validation. Geneva, Switzerland: World Health Organization; 2001.
  3. Bostrom KI, Jumabay M, Matveyenko A, Nicholas SB, Yao Y. Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res 2011; 108: 446-457.
  4. Li W, Salmon RM, Jiang H, Morrell NW. Regulation of the ALK1 ligands, BMP9 and BMP10. Biochem Soc Trans 2016; 44: 1135- 1141. Liu JJ, Foo JP, Liu S, Lim SC. The role of fibroblast growth factor 21 in diabetes and its complications: a review from clinical perspective. Diabetes Res Clin Pract 2015; 108: 382-389.
  5. Kaga T, Kawano H, Sakaguchi M, Nakazawa T, Taniyama Y, Morishita R. Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. Vascul Pharmacol 2012; 57: 3-9.
  6. Cuevas P, Outeirino LA, Angulo J, Gimenez-Gallego G. Chronic cystoid macular oedema treated with intravitreal dobesilate. BMJ Case Rep 2012; 2012: bcr2012006376. dell’Omo R, Semeraro F, Bamonte G, Cifariello F, Romano MR, Costagliola C. Vitreous mediators in retinal hypoxic diseases. Mediators Inflamm 2013; 2013: 935301. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
  7. Engerman RL, Kern TS. Hyperglycemia and development of glomerular pathology: diabetes compared with galactosemia. Kidney Int 1989; 36: 41-45.
  8. Engerman RL, Kern TS. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes 1993; 42: 820-825.
  9. Hohman TC, Nishimura C, Robison WG Jr. Aldose reductase and polyol in cultured pericytes of human retinal capillaries. Exp Eye Res 1989; 48: 55-60.
  10. Malik TG, Khalil M, Gul R, Ahmad SS, Munawar S. Serum versus vitreous VEGF A and central macular thickness in diabetic macular edema and the effect of intra-vitreal bevacizumab on these variables. Pak J Ophthalmol 2016; 32: 78-83.
  11. Christinger HW, Fuh G, de Vos AM, Wiesmann C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem 2004; 279: 10382-10388. Miyamoto N, de Kozak Y, Jeanny JC, Glotin A, Mascarelli F, Massin P, BenEzra D, Behar